Table 2.
Univariable analysis of the 3-year EFS and OS
| N | EFS |
OS |
||||||
|---|---|---|---|---|---|---|---|---|
| Events | 3-y EFS | P | Deaths | 3-y OS | P | |||
| Total | 191 | 87 | 0.52 (0.44-0.59) | 56 | 0.69 (0.61-0.76) | |||
| Sex | ||||||||
| Male | 107 | 48 | 0.52 (0.41-0.61) | .989 | 31 | 0.69 (0.58-0.78) | .902 | |
| Female | 84 | 39 | 0.52 (0.40-0.62) | 25 | 0.69 (0.57-0.78) | |||
| Age at HSCT, y | ||||||||
| <2 | 90 | 44 | 0.48 (0.37-0.59) | .328 | 26 | 0.71 (0.59-0.80) | .793 | |
| ≥2 | 101 | 43 | 0.55 (0.44-0.64) | 30 | 0.68 (0.57-0.76) | |||
| Age at diagnosis, y | ||||||||
| <1 | 92 | 52 | 0.40 (0.29-0.50) | .002 | 30 | 0.64 (0.52-0.74) | .220 | |
| ≥1 | 99 | 35 | 0.63 (0.52-0.72) | 26 | 0.73 (0.63-0.81) | |||
| Immunophenotype | ||||||||
| BCP | 156 | 78 | 0.47 (0.38-0.55) | .038 | 50 | 0.66 (0.57-0.73) | .160 | |
| T-cell ALL | 28 | 9 | 0.67 (0.46-0.81) | 6 | 0.78 (0.57-0.89) | |||
| Other | 6 | 0 | 1.00 (1.00-1.00) | 0 | 1.00 (1.00-1.00) | |||
| MRD before HSCT | ||||||||
| Cutoff ≥10−4 vs <10−4 | ||||||||
| Low | 105 | 49 | 0.50 (0.40-0.60) | .172 | 32 | 0.68 (0.57-0.77) | .384 | |
| High | 46 | 27 | 0.39 (0.24-0.53) | 19 | 0.58 (0.42-0.71) | |||
| Genetic aberration | ||||||||
| KMT2A-AFF1 | 51 | 28 | 0.41 (0.26-0.55) | .349 | 21 | 0.55 (0.39-0.68) | .164 | |
| ETV6-RUNX1 | 6 | 2 | 0.67 (0.19-0.90) | 1 | 1.00 (1.00-1.00) | |||
| BCR-ABL∗ | 13 | 5 | 0.59 (0.28-0.81) | 3 | 0.77 (0.44-0.92) | |||
| None of the above | 108 | 46 | 0.55 (0.45-0.64) | 29 | 0.71 (0.60-0.79) | |||
| Hypodiploidy | ||||||||
| No | 169 | 78 | 0.51 (0.43-0.59) | .962 | 49 | 0.70 (0.61-0.77) | .761 | |
| Yes | 2 | 1 | 0.50 (0.01-0.91) | 1 | 0.50 (0.01-0.91) | |||
| Hyperdiploidy | ||||||||
| No | 149 | 71 | 0.50 (0.41-0.58) | .181 | 46 | 0.68 (0.59-0.75) | .195 | |
| Yes | 23 | 8 | 0.65 (0.42-0.81) | 4 | 0.81 (0.56-0.92) | |||
| Donor | ||||||||
| MSD | 37 | 14 | 0.58 (0.39-0.73) | .382 | 10 | 0.73 (0.54-0.85) | .883 | |
| MUD | 154 | 73 | 0.50 (0.42-0.58) | 46 | 0.68 (0.59-0.75) | |||
| Remission status | ||||||||
| CR1 | 139 | 55 | 0.58 (0.49-0.66) | .035 | 34 | 0.74 (0.65-0.81) | .091 | |
| CR2 | 50 | 31 | 0.36 (0.22-0.49) | 21 | 0.57 (0.41-0.70) | |||
| CR3 | 2 | 1 | 0.50 (0.01-0.91) | 1 | 0.50 (0.01-0.91) | |||
| Remission status | .029 | |||||||
| CR1 | 139 | 55 | 0.58 (0.49-0.66) | .011 | 34 | 0.74 (0.65-0.81) | ||
| ≥CR2 | 52 | 32 | 0.36 (0.23-0.50) | 22 | 0.57 (0.41-0.69) | |||
| Stem cell source | ||||||||
| Bone marrow | 131 | 55 | 0.54 (0.45-0.63) | .264 | 37 | 0.70 (0.61-0.78) | .429 | |
| Peripheral blood | 35 | 21 | 0.39 (0.23-0.55) | 9 | 0.71 (0.52-0.84) | |||
| Cord blood | 23 | 11 | 0.52 (0.31-0.70) | 10 | 0.58 (0.34-0.76) | |||
| Bone marrow + peripheral blood | 1 | 0 | 1.00 (1.00-1.00) | 0 | 1.00 (1.00-1.00) | |||
| Time of relapse, mo | ||||||||
| <18 | 32 | 21 | 0.30 (0.14-0.47) | .577 | 13 | 0.60 (0.40-0.75) | .569 | |
| 18-30 | 15 | 9 | 0.40 (0.16-0.63) | 8 | 0.42 (0.16-0.66) | |||
| >30 | 1 | 0 | 1.00 (1.00-1.00) | 0 | 1.00 (1.00-1.00) | |||
| Type of relapse | ||||||||
| Bone marrow | 29 | 15 | 0.45 (0.26-0.63) | .017 | 9 | 0.66 (0.44-0.81) | .080 | |
| CNS | 10 | 7 | 0.27 (0.05-0.56) | 4 | 0.53 (0.17-0.80) | |||
| Other | 11 | 9 | 0.18 (0.03-0.44) | 8 | 0.36 (0.11-0.63) | |||
Data presented are probabilities and 95% CIs. BCP, B-cell precursor; CNS, central nervous system.
∗
Includes 1 patient with BCR-ABL and KMT2A-AFF1 and 2 patients with BCR-ABL and ETV6-RUNX1.